Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Transkaryotic Therapies (TKTX)

No earlier versions found for this Subject.

Return to Transkaryotic Therapies (TKTX)

Transkaryotic Therapies is an innovative biotech company whose niche technology is the production of commercial quantities of endogenous human proteins such as Epo by inserting constitutively active promoter regions upstream to the target gene in human cell lines. This method avoids the use of transgenes and non human cell lines which do not glycosylate proteins in precisely the native pattern. Many companies producing recombinant human proteins are threatened by TKTX's technology worried that their patents will not cover this novel method of protein production.